Latest News

Here's some of what is coming soon to NeurologyLive® this week.

Neurologists Sarah Simmons, MD, PhD, and Fatma Inanici, MD, PhD, discuss how the combination of noninvasive cervical spinal cord stimulation with exercise therapy can improve upper extremity function in people with MS.

A real-world comparative study found efgartigimod produced similar GBS disability score improvement to plasma exchange at 4 weeks, with significantly greater MRC sum score recovery at weeks 8 and 12, and a comparable safety profile.

Analysis of 1420 patients from the International GBS Outcome Study found no significant difference in GBS disability scores between IVIg and plasma exchange at 4 or 26 weeks after adjusting for key clinical covariates.

An exploratory analysis of the phase 3 ADHERE trial found serum NfL levels correlated with CIDP disease activity and declined with efgartigimod treatment in patients with elevated baseline levels.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is ferroptosis!

The CAPTIVATE trial evaluates claseprubart, an active C1s inhibitor, across a broad CIDP population including SOC responders, refractory patients, and treatment-naive adults, with time to relapse as the primary endpoint in the double-blind phase.

Despite missing its primary end point, the SYNAPSE-CMT trial showed improvements in muscle strength and motor function with ignaseclant treatment in patients with Charcot-Marie-Tooth disease.

A phase 4 trial underway in the U.S. is examining whether patients with CIDP on stable IVIg can transition to efgartigimod PH20 SC within one week of their last infusion, without requiring documented disease worsening first.

Pariceract missed meeting the primary and key secondary efficacy end points in the phase 2b ACTIVATE trial, leading to the discontinuation of its development for GBA1-associated Parkinson disease.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jessica Ailani, MD. [LISTEN TIME: 17 minutes]

Experts explore how stem cell therapies could transform the treatment of Parkinson disease, covering clinical trial progress, patient counseling challenges, and the potential to replace current standard-of-care approaches.

Romy Hoque, MD, Professor of Neurology at Emory University, previews the 2026 SLEEP Annual Meeting, highlighting key themes across neurodegeneration, hypersomnolence, sleep apnea, and the growing role of GLP-1 receptor agonists in sleep medicine.